Market News & Trends
Cardiovascular Patients on Aspirin Therapy Prefer VAZALORE 81 mg
PLx Pharma Inc. is a commercial-stage drug delivery platform technology company focused on its clinically validated and patent-protected PLxGuard that has the potential to improve…
Kymanox Announces First Executive Advisor: Fran DeGrazio
Kymanox Corporation is honored to announce Fran DeGrazio to the newly formed Kymanox Executive Advisors team. This team of highly distinguished industry executives has led…
Priority Review Granted for the First Oral & First New SERD in 20 years to Treat Metastatic Breast Cancer
The Menarini Group and Stemline Therapeutics recently announced the US FDA has accepted the company’s New Drug Application (NDA) for elacestrant, an investigational selective estrogen…
Synlogic Announces Synthetic Biotic for Gout Developed in Partnership With Ginkgo Bioworks
Synlogic, Inc. recently announced a new drug candidate for the treatment of gout developed in partnership with Ginkgo Bioworks The new candidate, SYNB2081, is a Synthetic…
Saama Collaborates With Merck to Build Machine Learning-Powered Clinical Data Layer to Strengthen Clinical Development Capabilities
Saama Technologies, LLC recently announced a multi-year agreement with Merck to build and operationalize a new clinical data layer leveraging Saama’s Life Science Analytics Cloud (LSAC) to….
Catalent to Acquire Metrics Contract Services for $475 Million
Catalent, Inc. recently announced it has reached an agreement to acquire Metrics Contract Services (Metrics), a full-service specialty Contract Development and Manufacturing Organization (CDMO) with a facility in….
VYNE Therapeutics Announces Results From Phase 2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
VYNE Therapeutics Inc. recently announced results from the Phase 2a segment of a Phase 1b/2a clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic…
BD, Labcorp Collaborate to Develop Flow Cytometry-Based Companion Diagnostics for Matching Patients With Treatments
BD (Becton, Dickinson and Company) recently announced a collaboration agreement with Labcorp, a leading global life sciences company, creating a framework to develop, manufacture, market and commercialize….
Valneva & Pfizer Initiate Phase 3 Study of Lyme Disease Vaccine Candidate
Valneva SE and Pfizer recently announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy, safety and….
Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8αβ T Cells From TCR-CAR+ Induced Pluripotent Stem Cells
Fate Therapeutics, Inc. recently announced the publication of preclinical study results demonstrating the successful generation, durable anti-tumor response, and functional persistence of TCR-CAR+ iPSC-derived CD8αβ…
Lexaria Bioscience Developing Powerful Tech to Treat Hypertension
Lexaria Bioscience Corp. recently announced its placement in an editorial published by NetworkNewsWir, one of 50+ trusted brands within the InvestorBrandNetwork, a multifaceted financial news…
Attralus Receives Orphan Drug Designation for AT-01 (Iodine (I-124) Evuzamitide)
Attralus, Inc. recently announced the US FDA has granted orphan drug designation for 124I-AT-01 (iodine (I-124) evuzamitide) as a diagnostic for the management of transthyretin…
Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma
Rain Therapeutics Inc. recently announced completion of enrollment in its Phase 3 MANTRA randomized, global, registrational trial of its lead product candidate, milademetan, an oral,…
BriaCell Secures License for Promising Novel Anti-Cancer Agent
BriaCell Therapeutics Corp. recently announced it has secured an exclusive license from University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80)…
Rigel Pharmaceuticals & Forma Therapeutics Announce Licensing Agreement for Novel Mutant IDH1 Inhibitor
Rigel Pharmaceuticals, Inc. and Forma Therapeutics, Inc. recently announced they have entered into an exclusive, worldwide license agreement to develop, manufacture, and commercialize….
US Patent Issued to HCW Biologics for Foundational Platform Technology
HCW Biologics Inc. was granted US Patent No. 11,401,324, which contains claims for immunotherapeutic compounds comprised of a single-chain chimeric polypeptide with two target-binding domains…
Ocuphire Extends US Patent Protection for Late-Stage Drug Candidate for Reversal of Mydriasis by 5 More Years Into 2039
Ocuphire Pharma, Inc. recently announced the issuance of US Patent No. 11,400,077. The patent provides added intellectual property protection for the company’s late-stage product candidate,…
Athira Pharma Presents Data From ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients
Athira Pharma, Inc. recently announced Hans Moebius, MD, PhD, Athira’s Chief Medical Officer, is leading an oral presentation titled ACT-AD: Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease…
Cornerstone Pharmaceuticals Announces Successful Completion of Phase 1b Clinical Trial
Cornerstone Pharmaceuticals, Inc. recently announced the successful completion of a Phase 1b clinical trial of CPI-613 (devimistat) in combination with gemcitabine and cisplatin for the treatment…
PolyPid Announces Exclusive Licensing Agreement With Advanz Pharma
PolyPid Ltd. recently announced it has entered into an exclusive licensing agreement with ADVANZ PHARMA Corp. for the commercialization of its lead drug candidate, D-PLEX100 for the prevention of….
